

Bubendorf, November 11, 2021

Bachem lays foundations for company's largest production building on Swiss National Future Day

- World's most modern production building for peptides and oligonucleotides to be built in Bubendorf
- Strengthening of the Bubendorf site as a leading center of excellence for the manufacture of complex pharmaceutical active ingredients
- Clear commitment to Switzerland as a location for business

Bachem (SIX: BANB) today laid the foundation stone for the company's largest production building to date at its main site in Bubendorf, Switzerland. The new building will expand Bachem's production capacities by 2024. It will be the world's most modern facility for the production of both peptides and oligonucleotides - complex molecules used in drugs to treat numerous diseases.

The building will add to Bachem's GMP-compliant production capacity for the manufacture of strictly regulated active pharmaceutical ingredients to Bachem's global network. In a first phase, it will provide up to 150 new highly skilled jobs.

Due to growing global demand, Bachem is pursuing an ongoing expansion of its worldwide production capacities. In Switzerland alone over CHF 150 million have been invested in the past five years at the Bubendorf and Vionnaz sites and more than 400 new jobs have been created. The search for a third site in Switzerland is currently underway, as the land reserves at the Bubendorf site will be exhausted in the medium term.

The laying of the foundation stone coincides with the Swiss National Future Day. On this day, young people learn about working at Bachem while visiting the company. Among other things, they will be able to carry out simple chemistry experiments in the training laboratory under the supervision of apprentices and tour the production facilities.

Thomas Meier, CEO: "I am delighted that we are commencing the construction of our largest production plant to date on National Future Day. Today has a special symbolism for Bachem. We are a company with a long-term mindset. Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have."

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

Bachem celebrates fifty years of company history. From Peter Grogg's business idea in the 1970s to the world's leading company in the development and production of peptides and oligonucleotides. A success story based on courage, innovation, quality, partnership, and unique people.

50 Years Bachem

For more information:

Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021

Media: media@bachem.com

Investors: ir@bachem.com